950 Winter Street
About Eloxx Pharmaceuticals
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 2,000 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA. with R&D operations in Rehovot, Israel.
YEAR FOUNDED: 2013
Chairman of the Board & CEO: Bob Ward
CMO: Dr. Pedro Huertas
CFO: Gregory Weaver
VP CMC: John van Duzer
Investor Relations: Barbara Ryan
VP Translational Science: Neal Sharpe
21 articles with Eloxx Pharmaceuticals
The week of June 18 to June 22 was bookended by a big hiring announcement in the pharma industry. It began with a former Cowen analyst being tapped as chief financial officer of startup Allogene and ended with the retirement announcement of the group worldwide chairman at Johnson & Johnson.
Eloxx Pharmaceuticals tapped Celgene veteran Neil Belloff as the company’s general counsel and corporate secretary.
Eloxx Appoints Global Pharmaceutical Leader, Neil Belloff, Executive Vice President, General Counsel and Corporate Secretary
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that it has appointed Neil Belloff, Executive Vice President, General Counsel and Corporate Secretary of Eloxx.
Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the 41st European Cystic Fibrosis Conference (ECFS)
Eloxx Pharmaceuticals, Inc. (“Eloxx”), (Nasdaq:ELOX), today announced positive data demonstrating that ELX-02 restores transmembrane conductance in and promotes forskolin-induced swelling (FIS).
Eloxx Pharmaceuticals Announces that Two Abstracts for ELX-02 Have Been Accepted for Presentation at the 41st European Cystic Fibrosis Conference
Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELX:OTCQ), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that two abstracts, including one Later Breaker, for its lead candidate, ELX-02 will be presented at the 41stEuropean Cystic Fibrosis Conference taking place on June 6-9, 2018 in Belgrade, Serbia.
The people at Eloxx Pharmaceuticals share a common goal — to bring safe and effective therapies to children and adults suffering from rare genetic diseases as quickly as possible.
Chairman and Chief Executive Officer, Robert E. Ward, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 1:30 p.m. EST at the Boston Marriott Copley Place.
Eloxx Pharmaceuticals Appoints Biotech Leader, Dr. Jasbir Seehra, Co-founder of Acceleron Pharma, to Board of Directors
Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELOX) (Other OTC:SVOND) a clinical-stage biopharmaceutical company developing novel read-through drug candidates that are designed to treat rare and ultra-rare premature...
Eloxx Pharmaceuticals, Inc. (“Eloxx”) (OTCQB: SVOND), a clinical-stage biopharmaceutical company developing novel small molecule medicines...
The Company will be known as Eloxx Pharmaceuticals following the completion of the transaction, and began trading on OTCQB Market under the new name effective as of December 20, 2017.
Eloxx today announced the two companies have completed their previously announced acquisition transaction effective as of December 19, 2017.
The trial is being run in Belgium, and data are expected at the end of the fourth quarter 2018.
Eloxx Pharmaceuticals Announces Expansion Of Intellectual Property Estate For ELX-02 With Newly Granted Patent In Europe
Sevion Therapeutics and Eloxx Pharmaceuticals announcedd that the European Patent Office (EPO) has granted a patent covering the Company's lead product candidate, ELX-02, as well as other proprietary compounds.
Eloxx Pharma Expands Management Team To Support Rapid Development Of Lead Drug Candidate ELX-02 For The Treatment Of Rare Genetic Diseases
Eloxx Pharma Secures US$8 Million Investment From LSP, Increasing Total Raised In Series C To US$38 Million
Eloxx Pharma Receives A US$6 Million Investment From KIP And DCS To Advance A Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis
Eloxx Pharma Receives A US$5 Million Investment From Quark Venture And GF Securities To Advance A Novel Disease-Modifying Therapy Targeting Genetic Diseases